Therapeutic Potential of an Anti-PLAC1 Antibody-Drug Conjugate in a Mouse Model of Human Breast Cancer

Background:Placenta-specific 1 (PLAC1) is an oncoplacental genes aberrantly expressed in various malignancies. Antibody-drug conjugates (ADC) offer a promising therapeutic approach by enhancing efficacy and reducing toxicity of treatment compared to cytotoxic small-molecule agents. Objective: To eva...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of immunology Vol. 22; no. 3; p. 192
Main Authors: Mahmoudian, Jafar, Ghods, Roya, Jeddi-Tehrani, Mahmood, Ghaffari-Tabrizi-Wizsy, Nassim, Nejadmoghaddam, Mohammad Reza, Ghahremanzadeh, Ramin, Ostad, Seyed Nasser, Zarnani, Amir-Hassan
Format: Journal Article
Language:English
Published: Shiraz Shiraz Institute for Cancer Research 30.09.2025
Subjects:
Angiogenesis
Antibodies
Breast cancer
Chorioallantoic membrane
Cytotoxicity
Enzyme-linked immunosorbent assay
Flow cytometry
Malignancy
Monoclonal antibodies
Oncofetal antigens
Pharmacokinetics
Spectrophotometry
Tumors
Xenografts
Placenta-specific 1 (PLAC1)
Breast cancer
Tumorigenesis
SN38
CAM
ISSN:1735-1383, 1735-367X, 1735-367X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background:Placenta-specific 1 (PLAC1) is an oncoplacental genes aberrantly expressed in various malignancies. Antibody-drug conjugates (ADC) offer a promising therapeutic approach by enhancing efficacy and reducing toxicity of treatment compared to cytotoxic small-molecule agents. Objective: To evaluate the efficacy of an SN38-conjugated monoclonal anti-PLAC1 antibody in a mouse model of breast cancer. Methods: Anti-human PLAC1 monoclonal antibodies were generated and characterized. SN38 was conjugated to an anti-PLAC1 antibody (clone: 2H12C12) and conjugation efficacy was determined by UV spectrophotometry. The antigen-binding activity of the conjugated antibody was assessed using ELISA and flow cytometry. In vitro , the cytotoxic profile of 2H12C12-SN38 was evaluated in MDA-MB-231 breast cancer cells using a fluoroimetric viability assay. The impact of 2H12C12-SN38 on MDA-MB-231 tumor growth and angiogenesis ex vivo was examined using chorioallantoic membrane (CAM) assay followed by immunohistochemical analysis. Pharmacokinetics of 2H12C12-SN38 in mice was determined by serial venipuncture following ADC administration. The inhibitory effects of anti-PLAC1 ADC on tumor growth were evaluated in a nude mouse xenograft model of human breast cancer. Results: The anti-PLAC1 ADC exhibited a substantial cytotoxicity against MDA-MB-231 cells, with effects observed at concentration as low as ~33 nM. In the CAM assay, the ADC significantly reduced the growth of MDA-MB-231 tumor but did not produce a significant effect on tumor angiogenesis. Pharmacokinetic analysis in mice demonstrated an average half-life (t1/2) of approximately 80 hours. In a nude mouse xenograft model, treatment with the ADC resulted in a significant reduction in tumor size compared with isotype-matched antibody-SN38 conjugate, or free SN38. Conclusion:This study represents the first therapeutic application of anti-PLAC1 ADC in a xenograft model of human breast cancer. Our findings support the embryonic origin of cancers and highlight the potential therapeutic value of targeting oncofetal antigens in human breast cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1735-1383
1735-367X
1735-367X
DOI:10.22034/iji.2025.106670.3019